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Drug discoveryA reference method for the antimicrobial susceptibility testing of common fungal pathogens such as dermato-
phytes, is currently lacking. In this study, we report the successful adaptation of solid agar-based spot culture
growth inhibition assay (SPOTi) for dermatophytes, currently being used as a gold-standard in the anti-
tubercular drug discovery ﬁeld. The fungal-SPOTi assay correlatedwith the disc-diffusionmethod, and is validat-
ed using mycelial plugs. We propose the fungal-SPOTi as a high-throughput alternative to the disc-diffusion and
broth micro-dilution anti-fungal assays to screen novel anti-fungals.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Dermatophytes, a group of fungi, are responsible for causing infec-
tion of the hair, skin and nails in one-ﬁfth of the world's population
(Marques et al., 2000). Treatment of fungal infections is not always
straight forward, for example, in onychomycosis, up to 50% of patients
in clinical practice are estimated to be treatment failures (Arrese and
Pierard, 2003) and 47% suffer a relapse, possibly as a result of incorrect
treatment and strain heterogeneity (Bradley et al., 1999). An immediate
solution to improve treatment outcomes is a rapid, straightforward and
accurate means to proﬁle the drug susceptibility of these fungal patho-
gens. This will allow clinicians to make an informed choice when pre-
scribing a therapy. While several drug susceptibility screening
methods for bacteria (Wiegand et al., 2008) and fungi such as yeasts
and ﬁlamentous fungi have existed for many years (Rex et al., 1993),
dermatophytes still lack an undisputable quantitative assay. An increase
in research activity related to anti-fungal susceptibility testing of der-
matophytes has led to the development of a number of broth micro-
and macro-dilution methods (Araujo et al., 2009), agar-based methods
using disc diffusion (Nweze et al., 2010; Macura, 1993); and E-Test
(Mendez et al., 2008), colorimetric modiﬁcations (Castro et al., 2007),
bioluminescence assays to enhance MIC determinations (Yoshida
et al., 1997). A limitation of many of these reported methods is theircl.ac.uk (S. Bhakta).
. This is an open access article underlong incubation times (up to 15 days) (Macura, 1993; Karaca and Koc,
2004). In addition, solid agar-based methods for dermatophytes often
report the minimum inhibitory concentration (MIC) of a drug as the
concentration at which the fungal growth showed a relative growth in-
hibition in percent, which can give rise to discrepancies owing to
operator-subjectivity (Ghannoum et al., 2006).
A rapid, but reliable method that is universally reproducible is need-
ed in both the clinical setting, where determination of antibiotic resis-
tance proﬁle is the goal, and the academic and/or industrial drug-
discovery wet-laboratories where irrefutable identiﬁcation of novel
lead molecules takes precedence. This calls for a stewardship engaged
in the development of assay techniques that are objective, gold-
standard and feasible.
We originally developed and previously reported a high-
throughput, solid agar-based assay conducted in multi-well (six-well
to ninety-six well) plates to test inhibitors of bacterial growth and via-
bility, known as the SPOTi assay (Evangelopoulos and Bhakta, 2010;
Gupta and Bhakta, 2012; Guzman et al., 2013). The latter has been inde-
pendently used in a clinical setting for antibacterial drug susceptibility
testing (Hall et al., 2012).
In this paper, we report the successful adaptation and application of
this methodology, which can be used to test anti-fungal drug suscepti-
bility as well as screening novel inhibitor libraries against fungal patho-
gens. At the ﬁrst instance, we tested four antifungal agents; amorolﬁne,
terbinaﬁne, ciclopirox olamine and nystatin against four dermatophyte
strains; Trichophyton rubrum, Trichophyton tonsurans, Trichophytonthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
The average conidial count and CFU of the dermatophytes.
Fungi Count (spores/ml) CFU (spores/ml)
T. rubrum 50 × 104 46 × 104
T. equinum 61 × 104 43 × 104
T. tonsurans 47 × 104 26 × 104
T. mentagrophytes 38 × 104 19 × 104
Table 2
MICs as determined from the SPOTi assay. (n = 3. Sd = 0 for all).
Fungi MIC (μg/ml)
Amorolﬁne Terbinaﬁne Ciclopirox Nystatin
T. rubrum 0.01 0.0006 2.5 1.2
T. equinum 0.005 0.0012 2.5 1.2
T. tonsurans 0.01 0.0012 1.2 0.6
T. mentagrophytes 0.02 0.0006 2.5 1.2
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using disc diffusion and mycelial plug methods.
2. Materials and methods
2.1. Materials
Four antifungal agents; amorolﬁneHCl (Ranbaxy Research Laborato-
ries, India), terbinaﬁne HCl (AK Scientiﬁc, USA) and ciclopirox olamine
(Insight Biotechnology Ltd, UK) and nystatin (Sigma Aldrich Ltd, UK)
were used. Sabouraud's dextrose agar (SDA), Sabouraud's dextrose
broth (SDB) and dimethyl sulfoxide DMSO were purchased from
Sigma-Aldrich, UK.
2.2. Isolates
Four dermatophytes strains T. rubrum (CBS 118892), T. tonsurans
(CBS 112818), T. equinum (CBS 127.97) and T. mentagrophytes (MUCL
9823) were used.
2.3. Methods
2.3.1. Preparation of inocula
Stock inoculum suspensions of the dermatophytes were prepared
from 14-day old cultures grown on Sabouraud's dextrose agar (SDA)
slants at 25 °C. The fungal colonies were covered with 2 mL of
Sabouraud's dextrose broth (SDB), and suspensions were obtained by
gently probing the surface of the agarwith the tip of a sterile Pasteur pi-
pette, generating a mixture of conidial and hyphal fragments. The ob-
tained suspensions were then ﬁltered through four layers of sterile
muslin, which retains hyphal fragments but permits the passage of der-
matophyte micro-conidia. A ﬁltration process was used as this has been
shown to provide a greater reproducibility and reliability of susceptibil-
ity testing.
The number of conidia permilli-litre (mL) of the inocula were deter-
mined by: 1) counting the number of conidia using a haemocytometerFig. 1. Schematic explanation of the spot cuand 2) determining colony forming units per mL (CFU mL−1) with
plate dilution assays and are shown in Table 1. For each isolate the num-
bers of conidia were determined in ﬁve viewing ﬁelds and averaged.
With the CFU determination, the results shown are the average of
three plates from three independent experiments in which strains
were harvested and counted.
2.3.2. High throughput SPOTi assay
The methodology, with required modiﬁcation from previously
published method (Guzman et al., 2013; Evangelopoulos and
Bhakta, 2010; Gupta and Bhakta, 2012), is schematically shown in
Fig. 1. Serial two fold dilutions of drug were prepared from a stock
solution in DMSO. Two μL of each dilution were dispensed into the
individual wells of a 96-well plate followed by the addition of
200 μL of SDA media using a Multidrop™ Combi multi-dispenser
(Thermo Scientiﬁc, UK). The ﬁnal drug concentration range in the
agar ranged between 10 and 0.005 μg/mL for ciclopirox olamine
and nystatin and 0.15 and 0.00007 μg/mL for terbinaﬁne HCl and
amorolﬁne HCl. The wells were then spotted using a multichannel
pipette with 5 μL of dermatophyte spore suspension. This was equiv-
alent to approximately 2000 dermatophyte spores per well.
SDAmedia was used as it was found to be one of the most favoured
for both soil and clinical dermatophytes isolates (Sharma and Sharma,
2011). An incubation temperature of 32 °C was used as these dermato-
phytes often infect keratinous tissue (Weitzman and Summerbell,
1995) such as skin, whose temperature is 32 °C. Furthermore, tempera-
tures of 30 to 35 °C have been shown to result in optimal fungal growth
and sporulation for T. rubrum and T. mentagrophytes (Sharma et al.,
2012). Dermatophyte growth was assessed visually over a period of
6 days (Fig. 1).
2.3.3. Disc diffusion susceptibility testing
Discs loaded with ciclopirox olamine, nystatin, amorolﬁne HCl and
terbinaﬁne HCl were prepared according to the potency in the Neo-
Sensitabs Susceptibility Testing Catalogue (Rosco Diagnostica Ltd,lture growth inhibition (SPOTi) assay.
Fig. 2. Susceptibility of T. rubrum to antifungal drugs using the 96-well plate SPOTi assay. The assay was performed in triplicates. Cic, ciclopirox; Nys, nystatin; Amo, amorolﬁne; Ter,
terbinaﬁne.
Table 3
ZOIs of ciclopirox, nystatin, amorolﬁne and terbinaﬁne against T. rubrum.
Mean ± standard deviation are shown (n= 3).
Antifungal agents Zone of inhibition (cm)
Ciclopirox 5.39 ± 0.31
Nystatin 2.65 ± 0.37
Amorolﬁne 9.00 ± 0.00
Terbinaﬁne 7.95 ± 0.32
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drug diffusion into the agar gel were 50 μg for ciclopirox olamine and
nystatin, and 5 μg for terbinaﬁne and amorolﬁne. 100 μl of T. rubrum in-
ocula was spread on the surface of SDA plates then the diffusion discs
were placed in the centre of the plates. The plates were then incubated
at 32 °C for 6 days. The diameters of ZOI were measured, using Image J
software. Results were averaged for 3 plates for each antifungal agent.
Fig. 3. Susceptibility of T. rubrum to ciclopirox olamine using mycelial plugs in 6-well plates.
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Using ciclopirox as amodel drug, the SPOTi assay described above in
96-well plates was validated using a 6-well plate and mycelial plugs of
5 mm diameter. Drug solutions were diluted in 5 ml SDA in each well
to produce drug concentrations of: 10, 5, 2.5, 1.2 and 0.6 μg/mL. In the
last well, the pure solvent (DMSO) was used to ensure that it does not
negatively affect fungal growth. T. rubrummycelial plugs of 0.6 mm di-
ameter were then placed in the centre of each well and incubated at
32 °C. This experiment was performed in triplicates. An additional 6-
well plate was used as a growth control where no antifungals or sol-
vents were mixed with SDA.3. Results and discussion
3.1. MICs determined by SPOTi, ZOI and mycelial plugs
With the modiﬁed SPOTi assay, dermatophyte growth was assessed
over a 6 day period after inoculation the MICs (Table 2.) of the antifun-
gal drugs could be reliably determined at day 3, as shown by photo-
graphic images shown in Fig. 2 for T. rubrum. Compared to the disc-
diffusion and broth micro-dilution methods, where a 7 day incubation
period is recommended (Norris et al., 1999), SPOTi offers a signiﬁcant
advantage and ease of performance.
Encouragingly, the results from the SPOTi, quantitative in nature,
agreed with the qualitative ones obtained from the disc-diffusion tests
(a qualitative analysis) that were performed alongside to validate the
former approach, i.e. a higher potency of amorolﬁne and terbinaﬁne
which gave larger ZOI at lower concentrations, compared to ciclopirox
and nystatin (Table 3).
Taking ciclopirox as a model drug, the SPOTi assay was compared
with the traditional method of inoculation using mycelial plugs
(Wright et al., 1983) (Fig. 3), where the MIC of ciclopirox was found
to be 2.5 μg/mL (Fig. 3). This is the same as that determined with
SPOTi (Table 2) and establishes the fact that, in spite of using only the
conidia of the fungi in the SPOTi assay, the MIC determination by
SPOTi is representative of all forms of the pathogen-hyphae and spores,
thereby displaying the robustness and reproducibility of the assay.
In the absence of a dermatophytes' susceptibility assessment stan-
dard, disc-diffusion method is still widely used primarily due to its con-
venience. The major critique of this method arises from the fact that
when a disc containing a given amount of an antifungal is placed onan agar plate, there follows a slow release of the drug out of the disc,
into the agar, followed by its diffusion within the agar over time. This
is likely to form a concentration gradient with higher drug concentra-
tions found near the drug-loaded disc. Thus dermatophytes further
away from the disc will be exposed to a lower drug concentration. Fur-
thermore, the interpretation of zone of inhibition (ZOI) can often be
subjective, with deﬁnitions of measured areas ranging from “area of
no growth” to “areas up to normal growth”. Finally, ZOI does not allow
the direct comparison of various agents in terms of MIC; and is only
qualitative even when areas of inhibitions are reported, as these values
cannot be used to determine MIC. For example, an area of more than
20 mm is indicative of susceptibility when testing terbinaﬁne but only
an area of 15 mm is indicative of susceptibility with nystatin (Rosco
Diagnostica Ltd, 2007/2008). Nonetheless, comparison of this method
with the broth micro-dilution assay has resulted in favourable correla-
tionwith some antifungal agents, where an increase of MIC is accompa-
nied by a decrease of inhibition zonediameters (National Committee for
Clinical Laboratory Standards, 1997; National Committee for Clinical
Laboratory Standards, 2002), as is also seen through this work
(Tables 2 and 3).
With the SPOTi assay, more quantitative results are obtained
through direct observation. Drug concentrations resulting in ‘no fungal
growth’ are identiﬁed as theMIC. Themain advantage of this assay, com-
pared to the disc diffusionmethod, is that the concentration of the drugs
that fungal colonies are exposed to is uniform in eachwell as the drug is
mixed thoroughly in the agar. Hence, SPOTi allows for quantitativemea-
surement of MICs.4. Conclusions
We have shown SPOTi to be a rapid, reliable and quantitative sus-
ceptibility assay for dermatophytes. The encouraging results attest to
the use of this assay on other fungi, for antifungal susceptibility testing
as well as for the screening of novel antifungal agents and it may
prove to be a gold-standard susceptibility assay for fungi. SPOTi has al-
ready proven to be a success story in the identiﬁcation of anti-
mycobacterials from varied sources such as natural, synthetic and has
recently been instrumental in repurposing drugs (Guzman et al.,
2013). We expect this success to translate effortlessly when using
fungi, and endeavour to adapt this convenient, effective technique for
other types of fungal pathogens.
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